ALEXION ACQUIRES PORTOLA PHARMACEUTICALS FOR $1.4 BILLION
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) coveted as the only approved FaxtorXa inhibitor reversal agent
Alexion Pharmaceuticals (NASDAQ: ALXN) has announced it is acquiring Portola Pharmaceuticals (NASDAQ: PTLA) for $1.41 billion in cash. Founded in 2003, Portola is based in South San Francisco and produces about $116 million in annual sales.
As a biotechnology company, Portola specializes in thrombotic and other hematologic disorders
Portola presently has two primary products. Bevyxxa (betrixaban) is an oral anticoagulant indicated for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) is a recombinant modified human factor Xa (FXa) protein indicated for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. It is administered through IV infusion.
Portola’s pipeline candidates include:
- Andexanet Alfa is positioned for indications aligned with the reversal of Factor Xa inhibitors and urgent surgery
- Cerdulatinib is a dual-spleen tyrosine kinase and Janus kinase (SYK/JAK) inhibitor with the potential to gain indications for peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL) and follicular lymphoma
Alexion is a leader centered on the creation of novel, advanced biotherapies
Headquartered in Boston, Alexion generates about $5.5 billion in annual sales. Founded in 1992, they specialize in developing and commercializing high specialized biotherapeutics and other medicines for the treatment of rare diseases. Other noteworthy rare disease companies Alexion could be compared to are:
In April 2020, Alexion launched a phase 3 study to investigate the safety and efficacy of Ultomiris (ravulizumab‑cwvz), a monoclonal antibody C5 inhibitor as a treatment for COVID-19. The product is presently FDA approved for the treatment of paroxysmal nocturnal hemoglobinuria, a rare blood disease that triggers red blood cells to break apart and release hemoglobin (the carrier in red blood cells that transports oxygen to cells).
The unique and highly advanced products within Portola’s portfolio and pipeline are an ideal fit for Alexion’s focus on rare diseases.
Thank you for reading this story
Read my other articles about medical and healthcare business trends, content marketing and digital strategy, brand and product management, consumer wellness, managed care and market access strategy. Contact me today for your healthcare content writing and content strategy needs.
I have over 20 years of experience in the healthcare industry producing valuable healthcare content for audiences and customers spanning physicians, nurses, pharmacists plus pharmaceutical companies, medical technology manufacturers, healthcare provider organizations, managed care, investors, consumers and other stakeholders.
Visit and connect…
As a healthcare content writer, my work aligns with an organization’s voice, brand, SEO elements, marketplace and objectives. It establishes trust in their company and recognized value in its products and services that generates revenue.
This experience was earned through working at Walgreens, Pfizer, AbelsonTaylor, TAP (Takeda Abbott Partnership), Hospira Worldwide and Boston Software Systems.
To a large degree, my professional interests emulate my family which includes doctors, nurses, physician assistants and other clinicians plus those that are working in healthcare administration and commercial enterprises.
See this article on Slide Share!